FeesSafety
Pluang+

eGain to report Q1 fiscal 2027 earnings on November 5, 2026

Company Fundamentals
26 Oct 2026, 23:05 WIB
GlobeNewsWire
View Source
Neutral
eGain to report Q1 fiscal 2027 earnings on November 5, 2026

eGain Corporation will announce its fiscal 2027 first quarter financial results after market close on November 5, 2026. The announcement will be followed by a conference call and webcast hosted by CEO Ashu Roy and CFO Eric Smit. Investors can access the live call via phone or webcast on eGain's website. This update is important for shareholders and potential investors tracking eGain's performance in AI-powered customer experience solutions.

For readers following eGain's upcoming fiscal 2027 first quarter results announcement, here is Pluang's Technology sector market snapshot as of Oct 27, 2026 02:51 WIB: Among 150 priced US Technology stocks, 81 rose and 65 fell. Notable movers include Synopsys, Inc. (SNPS) at USD 456.19 with a 1-day change of +6.06% and typical hold time of 72 days, Expensify Inc (EXFY) at USD 2.44 down -5.79% with a 41-day hold, and VNET Group Inc (VNET) at USD 3.93 up +5.79% with a 17-day hold. Pluang order activity shows SNPS with 68% sell and 32% buy, EXFY with 84% sell and 16% buy, and VNET evenly split at 50% sell and 50% buy.

More News

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...

Company Fundamentals
Neutral
23 minutes ago
Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...

Market News
Bullish
23 minutes ago
S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...

Market News
Bullish
35 minutes ago
SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

Public companies are facing new challenges for the 2027 proxy season due to changes in SEC policies, evolving shareholder activism strategies, and shifts in institutional investor voting. A virtual roundtable on October 28 will gather experts to disc...

Market News
Neutral
2 hours ago
Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo Inc., a leading provider of in-flight broadband connectivity, announced it will report its third quarter 2026 financial results on November 6, 2026, before the market opens. The company will hold a conference call with financial analysts the sam...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App